Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis

Journal of the National Cancer Institute

Volumn 95, Issue 6, 2003, Pages 437-448

  von Marschall, Zofia ^a   Scholz, Arne ^a   Cramer, Thorsten ^a   Schäfer, Georgia ^a   Schirner, Michael ^b   Öberg, Kjell ^c   Wiedenmann, Bertram ^a   Höcker, Michael ^a   Rosewicz, Stefan ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; LIVER BIOPSY; LIVER METASTASIS; MALE; MICROVASCULATURE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; PANCREAS CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 0037454239     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.6.437     Document Type: Article

References (36)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
4. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
5. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
6. Gutterman JU. Cytokine therapeutics: lessons from interferon-alpha. Proc Natl Acad Sci U S A 1994;91:1198-205.
7. Star GA, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
8. Albini A, Marchisone, C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000;156:1381-93.
9. Sgonc R, Fuerhapter C, Boeck G, Swerlick R, Fritsch P, Sepp N. Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol 1998;117:209-14.
10. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-6.
11. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Down-regulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc Natl Acad Sci U S A 1992;89:9049-53.
12. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.
13. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
14. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92-7.
15. Gaudin PB, Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. Am J Surg Pathol 1995;19:642-52.
16. Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines GK 3rd, et al. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumors. Eur J Cancer 1998;34:2046-52.
17. von Marschall Z, Cramer T, Höcker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001;48:87-96.
18. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
19. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997;15:669-76.
20. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996;383:344-7.
21. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997;16:750-9.
22. Philipsen S, Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999;27:2991-3000.
23. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35.
24. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62.
25. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
26. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
27. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
28. Neufeld G, Cohen T, Gengrinovitch S, Potorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
29. Levy DE. Analysis of interferon-regulated protein binding the interferon-alpha-stimulated response element. Methods 1998;15:167-74.
30. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
31. Majello B, De Luca P, Lania L. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J Biol Chem 1997;272:4021-6.
32. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, et al. Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem 2000;275:22769-79.
33. Jackson SP, MacDonald JJ, Lees-Miller S, Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 1990;63:155-65.
34. Jackson SP, Tjian R. O-Glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell 1988;55:125-33.
35. Ryu S, Zhou S, Ladurner AG, Tjian R. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 1999;397:446-50.
36. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-64.